Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic...

Related Keywords

Houston ,Texas ,United States ,America ,Isabella Zinck ,Vivek Subbiah ,Prnewswire Novartis ,Samir Shah ,Parag Mahanti ,Sloan Simpson ,Alina Levchuk ,Reshema Kemps Polanco ,Division Of Cancer Medicine ,University Of Texas Md Anderson Cancer Center ,Twitter ,Drug Administration ,Novartis ,Exchange Commission ,Approval Program ,Rare Oncology Agnostic Research ,Novartis Pharmaceuticals Corp ,Clinical Center ,Accelerated Approval Program ,Investigational Cancer Therapeutics ,Targeted Therapy ,Cancer Medicine ,Cancer Center ,Novartis Oncology ,Important Safety ,Prescribing Information ,East Hanover ,Top Microbiol ,Novartis Us ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Fda Approval ,Clinical Trials Amp Medical Discoveries ,